Recombinant Mouse Noggin Protein

Description :
FAQ COA 已发表文献 Noggin is a bone morphogenetic protein (BMP) antagonist expressed in Spemann’s organizer. It inhibits TGF- family ligands and preventing them from binding to their corresponding receptors. Noggin was originally found as a BMP-4 antagonist, and then has been shown to modulate the activities of other BMPs (BMP-2, 7, 13 and 14).Noggin is very highly conserved among vertebrates, such that mature human Noggin shares 99%, 99%, 98%, 97% and 89%aa sequence identity with mouse, rat, bovine, equine and chicken Noggin, respectively. Secreted noggin protein regulates bone morphogenetic protein activity during development.The Role of the BMP Signaling Antagonist Noggin in the Development of Prostate Cancer Osteolytic Bone Metastasis. Lack of expression of the BMP antagonist noggin by osteoinductive, carcinoma-derived cell lines is a determinant of the osteoblast response induced by their bone metastases. In contrast, osteolytic, carcinoma-derived cell lines express noggin constitutively. Product Properties Synonyms NOG, SYM1, symphalangism 1 (proximal), synostoses (multiple) syndrome 1, SYNS1, SYNS1A Accession P97466 GeneID 18121 Source E.coli-derived humanNogginprotein, Gln28-Cys232, with an N-terminal Met. Molecular Weight Approximately 46.4kDa. AA Sequence MQHYLHIRPA PSDNLPLVDL IEHPDPIFDP KEKDLNETLL RSLLGGHYDP GFMATSPPED RPGGGGGPAG GAEDLAELDQ LLRQRPSGAM PSEIKGLEFS EGLAQGKKQR LSKKLRRKLQ MWLWSQTFCP VLYAWNDLGS RFWPRYVKVG SCFSKRSCSV PEGMVCKPSK SVHLTVLRWR CQRRGGQRCG WIPIQYPIIS ECKCSC Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity >95%by SDS-PAGE and HPLC analyses. Biological Activity The ED50as determined by inhibiting BMP-4-induced alkaline phosphatase production of murine ATDC5 cells is less than 2 ng/mL, corresponding to a specific activity of > 5.0 105IU/mg in the presence of 5 ng/mLBMP-4.Fully biologically active when compared to standard. Endotoxin 1.0EUper 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered concentrated solution in30%acetonitrile, 0.1%TFA. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10 mM HAc to a concentration less than 0.25 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20. Further dilutions should be made in appropriate buffered solutions.